Clinical Trial Phases | UPMC Hillman Cancer Center

Phase II trial of nivolumab and axitinib in anti-PD-1 refractory melanomaПодробнее

Investigator Perspectives on Available Research and Challenging Questions in Melanoma and Nonmela...Подробнее

Phase I/II trial of dazostinag with or without pembrolizumab in advanced solid tumorsПодробнее

Spotlight on Immunotherapy at ASCO22Подробнее

PAA Presents withUPMC Hillman Cancer Center: The Future of Cancer Research and VaccinesПодробнее

Repurposing Disulfiram to Overcome Chemotherapy Resistance in Relapsed SarcomasПодробнее

Assessing NSCLC treatments in under-represented patient populationsПодробнее

PAA Presents with UPMC Hillman Cancer Center: Spring Into Summer Taking Care of the Skin You're InПодробнее

KEYNOTE-716: long-term efficacy and safety of pembrolizumab in resected melanomaПодробнее

ASCO22: Key Posters on Advances in ImmunotherapyПодробнее

Pixatimod and nivolumab in metastatic melanoma, NSCLC and MSS CRCПодробнее

Protocol Office and Clinical Research CoordinationПодробнее

Results of a Phase II trial of vidutolimod and nivolumab in melanomaПодробнее

UPMC Hillman Cancer CenterПодробнее

PAA Presents with UPMC Hillman Cancer Center: The Latest Findings in Cancer Research and VaccinesПодробнее

ARTACUS: exploring the RP1 oncolytic virus for the treatment of cancer patients with CSCCПодробнее

Clinical Trials and Immunotherapy for Head and Neck CancerПодробнее

UPMC Hillman Cancer Center | April 1, 2023Подробнее

Clinical Trials and Immunotherapy for Head and Neck CancerПодробнее

Winship Grand Rounds: June 15, 2022 - Dan Zandberg, MDПодробнее